Endocrinology

During follow-up, 2.6% of the patients were diagnosed with depression, while 32.1% were treated with antidepressants.

Women with endometriosis had a 34% greater risk of stroke than women without the chronic inflammatory gynecological condition, according to an analysis of the Nurses Health Study II.

The Duke expert reviews key strategies for starting and continuing care with the pivotal glycemic control agent.

An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.

An analysis of claims data from more than 150,000 patients with pediatric obesity, results of the study led investigators to call for specific, actionable guidelines outlining proper testing and screening procedures in this patient population.

Despite some reports detailing concerning trends in weight gain and inactivity during the COVID-19 pandemic, an analysis of medical record data from 4.25 million US adults suggests the mean weight gain was just 0.1 kg greater than the preceding year.

An analysis of more than a decade of follow-up data from patients with obesity who underwent Roux-en-Y gastric bypass details the impact participation in educational programs after surgery can have on long-term weight loss outcomes.

Released on July 7, the 2022 hormone therapy position statement from the North American Menopause Society is 28 pages in length and has received endorsement from 20 international organizations, including the AACE.

There was no association found between ever using metformin and the risk of either IBD, Crohn’s disease, or ulcerative colitis.

An analysis of nationally representative data from NHANES cycles from 1999-2000 through 2017-2018 suggests just 6.8% of US adults had optimal cardiometabolic health.

Dr. Gregory Weiss provides perspective on data from the American Society for Metabolic and Bariatric Surgery 2022 Annual meeting suggesting patients who underwent bariatric surgery reduced their risk of cancer later in life.

New data from a study performed by investigators at UVA Health details the accuracy of blood glucose measurements with factory-calibrated CGMs in patients undergoing dialysis.

With the first 6 months of 2022 behind us, Endocrinology Network has compiled a list of the top approvals in diabetes care from the first half of the year. The list includes multiple approvals for CGM, a first-in-class agent, and an increased dose of a popular GLP-1 RA.

Dr. Jennifer Green led a panel in discussing new treatments and topics in diabetes care.

An analysis of data from NHANES details trends in lifestyle behaviors, including healthy eating and physical activity, among patients who have undergone bariatric surgery compared to those considered eligible for surgery and those of normal weight.

After using eye care examination results as a reference standard, the accuracy of PCP fundoscopic examination was 62.7%.

An analysis of weight gain trends among more than 10,000 US adults suggests nearly 1-in-5 experienced a weight gain of 20% or more during the previous 10 years.

Our endocrinology month in review spotlights the most popular content from the past month. The top content from June includes data from ADA 2022, new episodes of Diabetes Dialogue, & more.

According to a new study, cumulative exposure to PFAS during midlife can increase the risk of incident hypertension among women as they age, with those in the highest tertile of cumulative exposure at a 71% greater risk of developing hypertension.

New data from the SKYLIGHT 2 trial demonstrate the reductions in frequency and severity of vasomotor menopausal symptoms in midlife women associated with the use of fezolinetant as well as potential improvements in sleep associated with use of the neurokinin-3 receptor antagonist from Astellas Pharma.

In the fourth and final episode from ADA 2022, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.

In the third special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, Jasmine Gonzalvo, PharmD, joins hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss prevailing barriers in diabetes management, including access to new pharmacologic agents as well as newer diabetes technologies.

In our second special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, hosts Drs. Diana Isaacs and Natalie Bellini are joined by Gary Scheiner, MS, CDE. Clinical director of Integrated Diabetes Services, author of multiple books, including Think Like a Pancreas: A Practical Guide to Managing Diabetes with Insulin, and former Diabetes Educator of the Year, Scheiner joins Diabetes Dialogue to provide a deep dive into the largest diabetes meeting of the year from the view of a diabetes care and education specialist.

In the first of 4 special edition ADA 2022 episodes, hosts Drs. Diana Isaacs and Natalie Bellini take on the role of interviewers and discuss CGM uptake in primary care with Drs. Sean and Tamara Oser. Later in the episode, the pair provide perspective on their experiences with Beta Bionics's Insulin-Only Bionic Pancreas.

Although typically associated with an increased risk of type 2 diabetes, new research from Israel presented at ADA 2022 suggests increased BMI in adolescence was associated with an increased risk of new-onset type 1 diabetes in young adulthood.

At ADA 2022, Endocrinology Network sat down with Lindsay Mayberry, PhD, to discuss a pair of studies she presented examining trends in CGM uptake and correlates associated with increased uptake in primary care settings.

Prof. Hertzel Gerstein discusses new ELIXA biomarker findings from ADA 2022.

The diabetologist and professor discusses new findings from the ReTUNE trial, which disparage the utility of BMI in defining diabetes risk and remission opportunity.

New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.

A month and a half after topline results were announced in April, full data from SURMOUNT-1 was presented at ADA 2022 and demonstrate tirzepatide in 5 mg, 10 mg, or 15 mg doses provides superior weight loss compared to placebo therapy, with this weight loss maintained throughout the duration of the trial.